摘要
目的 观察选择性α1A受体阻滞剂盐酸坦索罗辛 (哈乐 )治疗伴高血压的良性前列腺增生 (BPH)患者时是否影响原有抗高血压药物对血压的控制。 方法 采用临床多中心开放试验 ,给187例经常规抗高血压药治疗后血压已稳定控制的BPH患者服用哈乐 ,根据所用抗高血压药的不同 ,分 6组进行分析。 结果 治疗前后比较 :国际前列腺症状评分 (IPSS)明显下降 ,由 2 1.2 5±5 .83降至 11.86± 5 .0 1,平均下降 10 .11± 5 .2 5 (P <0 .0 0 1) ;最大尿流率由 (10 .2 5± 3.5 5 )ml/s升至(13.5 8± 3.6 1)ml/s ,平均增加 (3.2 1± 2 .74)ml/s(P <0 .0 0 1) ;剩余尿由 (37.6 7± 5 6 .96 )ml降至(16 .77± 34 .12 )ml,平均下降 (2 5 .79± 34 .2 3)ml(P <0 .0 0 1)。 2例因严重血压下降而退出试验 ,2例出现心悸、心慌 ,其余患者血压和心率无明显改变 (P >0 .0 5 ) ;2 9例患者出现副反应 30例次 ,副反应发生率 15 .5 %。 结论 哈乐治疗伴有高血压的BPH患者时与常规抗高血压药合用安全、有效 ,不影响抗高血压药对血压的控制 。
Objective To evaluate the efficacy and tolerability of tamsulosin together with conventional anti hypertension drugs in patients with benign prostatic hyperplasia (BPH) and hypertention. Methods An open multicenter clinical study was undertaken on 187 patients with BPH and hypertension,which were divided into 6 groups, according to the different anti hypertention drugs. Results All the subjective and objective parameters were found to be significantly improved after the treatment. Of the 185 patients (2 cases were excluded from the study because of marked drop of blood pressure),IPSS decreased significantly from 21.25±5.83 to 11.86±5.01 with a mean drop of 10.11±5.25 ( P <0.001). Of 170 patients with integrated urine flow meter data, the maximal flow rate increased from (10.25±3.55)ml/s to (13.58±3.61)ml/s,with a mean increase of (3.21±2.74)ml/s ( P <0.001). In 103 patients , the residual urine decreased significantly from (37.67±56.96)ml to (16.77±34.12)ml,with a mean decrease of (25.79±34.23)ml ( P <0.001). Adverse side effects occurred in 15.5% (29/187).Serious hypotension occurred in 2 whereas the rest 185 patients showed no significant change in blood pressure( P >0.05). Heart rate also showed no significant change except 2 patients ( P >0.05). Conclusions Tamsulosin, combined with anti hypertension drugs,could be effectively and safely used in patients with BPH and concomitant Hypertension.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2002年第1期35-37,共3页
Chinese Journal of Urology
